GSK plc Stock
Price
Target price
€15.04
€15.04
1.430%
0.212
1.430%
?
30.09.22 / Tradegate
WKN: A3DMB5 / Symbol: GLAXF / Name: GSK / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
GSK plc Stock
GSK plc gained 1.430% today.
Our community is currently high on GSK plc with 3 Buy predictions and 1 Sell predictions.
On the other hand, the target price of €15.00 is below the current price of €15.04 for GSK plc, so the potential is actually -0.292%.
So far the community has only identified positive things for GSK plc stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of GSK plc in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
B****
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of GSK plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| GSK plc | 1.430% | 1.334% | -9.198% | -8.935% | -23.245% | -23.064% | -12.525% |
| AstraZeneca plc | 1.210% | -0.377% | -11.700% | 8.900% | 8.522% | 36.452% | 97.801% |
| Merck KGaA | 1.590% | 4.132% | -3.128% | -11.838% | -27.356% | 59.865% | 74.795% |
| Eli Lilly Corp. | -1.710% | 2.714% | 7.697% | 65.597% | 33.901% | 221.895% | 355.323% |
Comments
News
GSK prepares US for 2022-23 flu season with over 50 million influenza vaccine doses
GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its quadrivalent influenza vaccines to US healthcare providers and pharmacies in preparation for the 2022-23 season. This
GSK Selects Target the Future Grant Recipient in Innovation Challenge Supporting Multiple Myeloma Community
GSK plc today announced the first recipient of the Target the Future Think Tank Challenge £70,000 (equivalent to approximately $100,000) grant to the HealthTree Foundation, a non-profit
Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis
Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis
